DALLAS, April 26, 2014 /PRNewswire/ --
RnRMarketResearch.com offers Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant and HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth research reports in its store.
Human Immunodeficiency Virus (HIV) treatment market value will increase at a slow pace in the coming years, from $14.3 billion in 2012 to $16.3 billion by 2019, at a Compound Annual Growth Rate (CAGR) of 1.9% due to patent expirations of several key therapies says the report HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth available at http://www.rnrmarketresearch.com/hiv-therapeutics-in-major-developed-markets-to-2019-limited-pipeline-efficacy-improvement-patent-expirations-and-stringent-healthcare-spending-to-suppress-market-growth-market-report.html .
The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. These include the impact of the drugs approved in the forecast period, but also the increase in the prevalence of the disease and minor improvements in diagnostics that result in more patients being eligible for pharmacological as per the report Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant available at http://www.rnrmarketresearch.com/pancreatic-adenocarcinoma-therapeutics-in-major-developed-markets-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant-market-report.html .
As per HIV Therapeutics in Major Developed Markets to 2019 - Limited Pipeline Efficacy Improvement, Patent Expirations and Stringent Healthcare Spending to Suppress Market Growth report, the first-line antiretroviral therapies Atripla and Truvada will lose patent protection during the forecast period, which will hurt their markets in Europe and Canada. Analyst of this report says: "Despite such patent losses, a number of drugs will enter the HIV market by 2019. Among these new entrants, 572-Trii is expected to perform the strongest commercially and will compete with Atripla following its approval. However, these drugs will not offset the impact of generic erosion."
Currently, the HIV pipeline is strong and displays a high degree of novelty and diversity, according to this research. The pipeline also consists of therapies that address the unmet needs of drug resistance and toxicity. These drugs are Nucleoside Reverse Transcriptase Inhibitor (NRTI) apricitabine, censavudine and elvucitabine, which deal with the issue of NRTI resistance.
Another candidate in the HIV pipeline, which is a new pro-drug of tenofovir, called tenofovir alafenamide, has also demonstrated a more favorable toxicity profile than its predecessor Viread.
The analyst further says: "Despite the promising outlook, the HIV pipeline has suffered from high attrition rates in recent years, particularly with vaccines. None of these have been approved for the treatment of HIV. These failures reflect an urgent need for a more thorough understanding of immune response against HIV and more streamlined clinical trial designs". Order a copy of the HIV therapeutics market at http://www.rnrmarketresearch.com/contacts/purchase?rname=168415 .
Products discussed in the Pancreatic Adenocarcinoma Therapeutics in Major Developed Markets to 2019 - Early Stage Pipeline Shows Diversity of Novel Targets though Commercial Impact Remains Distant report include Gemcitabine, IV Fluorouracil, Tarceva, Abraxane, Teysuno/TS-1, Xeloda and Eloxatin. The promising drug candidates in pipeline discussed in this research are Masivet/Kinavet (US) - AB Science, Glufosfamide - Eleison Pharmaceuticals Incorporated Tertomotide - Kael-GemVax Co., Ltd TH-302 - Threshold Pharmaceuticals HyperAcute Pancreas - NewLink Genetics Corporation and MM-398 - Merrimack Pharmaceuticals Inc. Following industry licensing and co-development deals have been discussed in this report:
- Clavis Enters Licensing and Development Agreement with Clovis
- Baxter Enters Licensing Agreement with Onconova for Rigosertib
- Lorus Therapeutics Enters Into Licensing Agreement with Zor Pharma
- Novogen Enters Into Licensing Agreement with Marshall Edwards For NV-196 And NV-143
- Merck Serono Enters Into Co-Development Agreement with Threshold Pharma for TH-302
Pancreatic Adenocarcinoma Therapeutics Market forecasts to 2019 have been provided for global region as well as US, Canada, UK, France, Germany, Italy, Spain and Japan. Order a copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=168412 .
Explore more reports on the therapeutics market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics and on the pharmaceuticals market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals .
About Us:
RnRMarketResearch.com (http://www.rnrmarketresearch.com/ ) is an online market research reports library of 400,000+ in-depth studies of over 5000 micro markets. Our database includes reports by leading publishers from across the globe. We provide 24/7 online and offline support service to our customers.
Contact:
Priyank Tiwari
TX, Dallas North - Dominion Plaza,
17304, Preston Road,
Suite 800, Dallas 75252
Tel: +1-888-391-5441
sales@rnrmarketresearch.com
http://www.lifescienceindustryresearch.com/latest-reports
Connect With Us on:
Facebook:http://www.facebook.com/pages/RnR-Market-Research/413488545356345
Twitter:https://twitter.com/RnRMR
G+:https://plus.google.com/u/0/104156468549256253075/
RSS:http://www.rnrmarketresearch.com/feed
